Department of Pediatric Cardiology, Madras Medical Mission, Chennai, India.
Department of Pediatric Cardiology, Madras Medical Mission, Chennai, India.
Indian Heart J. 2020 Sep-Oct;72(5):369-375. doi: 10.1016/j.ihj.2020.07.019. Epub 2020 Jul 28.
Left atrial appendage occlusion (LAAO) in non-valvar atrial fibrillation (AF) reduces cardioembolic strokes. Despite increased risk, trials exclude valvar AF in structural heart diseases where clots extend beyond appendage.
Patients with AF and relative risks for oral anticoagulation (OAC) needing structural interventions underwent concomitant LAAO. After six months of OAC, aspirin was continued. Transesophageal echocardiogram was done three monthly till one year and yearly thereafter. The patient demographics, procedural details, post-procedural follow-up were analyzed.
Nine patients aged 51.5 ± 6.3 years with AF underwent LAAO concomitantly with balloon mitral valvotomy in four patients, atrial septal defect device closure in four and periprosthetic mitral leak closure in one patient. Six patients had heart failure, four had prior embolic events, and two had documented LAA thrombus. The mean CHADSVASc score was 2.44 ± 0.8 and mean HASBLED score was 3.0 ± 0.8. Devices included Amplatzer Cardiac Plug™ in six patients, LAmbre™ Lifetech device in two and Watchman™ device in one. All procedures were successful without acute complications. A patient developed pericardial effusion at six months requiring pericardiocentesis. Early device-associated thrombus in one patient resolved after OAC for six months. No embolic events occurred on follow-up.
On a detailed literature search, this largest LAAO experience in structural heart diseases indicates its utility. OAC for six months followed by aspirin seems to prevent thrombus formation in these patients. The only incidence of early thrombus formation indicates immunity from clot formation after device endothelialisation. Larger multicenter trials combining LAAO with structural interventions in valvular AF are warranted in developing nations.
左心耳封堵(LAAO)在非瓣膜性心房颤动(AF)中可减少心源性栓塞性中风。尽管风险增加,但试验排除了结构性心脏病中的瓣膜性 AF,因为血栓延伸超出了心耳。
患有 AF 且需要结构性介入的口服抗凝剂(OAC)相对风险患者接受了同期 LAAO。OAC 治疗 6 个月后,继续使用阿司匹林。在接下来的一年中,每 3 个月进行一次经食管超声心动图检查,然后每年进行一次。分析患者的人口统计学特征、手术细节和术后随访情况。
9 名年龄为 51.5±6.3 岁的 AF 患者同时接受了 LAAO,其中 4 名患者进行了球囊二尖瓣成形术,4 名患者进行了房间隔缺损装置闭合术,1 名患者进行了瓣周漏关闭术。6 名患者有心衰,4 名患者有栓塞事件史,2 名患者有记录的左心耳血栓。平均 CHADSVASc 评分为 2.44±0.8,平均 HASBLED 评分为 3.0±0.8。使用的装置包括 Amplatzer 心脏塞™6 例,LAmbre™ Lifetech 装置 2 例,Watchman™装置 1 例。所有手术均成功,无急性并发症。1 例患者在术后 6 个月出现心包积液,需行心包穿刺引流。1 例患者在 OAC 治疗 6 个月后早期出现的设备相关血栓溶解。随访期间无栓塞事件发生。
通过详细的文献检索,这项结构性心脏病中最大的 LAAO 经验表明其具有实用性。OAC 治疗 6 个月后再使用阿司匹林似乎可以预防这些患者的血栓形成。唯一发生的早期血栓形成表明,在设备内皮化后,血栓形成的免疫力得到了增强。在发展中国家,需要进行更大规模的多中心试验,将 LAAO 与瓣膜性 AF 的结构性介入相结合。